Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats

Kidney International

Volumn 79, Issue 11, 2011, Pages 1186-1197

  Rouse, Rodney L ^a   Zhang, Jun ^a   Stewart, Sharron R ^a   Rosenzweig, Barry A ^a   Espandiari, Parvaneh ^a   Sadrieh, Nakissa K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

gene expression; histopathology; proximal tubule; renal injury; urine proteomics

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CLUSTERIN; GENTAMICIN; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE MU; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOPONTIN; RENAL PAPILLARY ANTIGEN 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HISTOPATHOLOGY; KIDNEY COLLECTING TUBULE; KIDNEY INJURY; KIDNEY NECROSIS; KIDNEY TUBULE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEOMICS; RAT; TISSUE REGENERATION; UNITED STATES; UREA NITROGEN BLOOD LEVEL;

EID: 79956039678     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.463     Document Type: Article

References (35)

1. Goodsaid F, Frueh F. Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J 2007; 9: E105-E108.
2. Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008; 245: 219-223.
3. Goodsaid FM, Blank M, Dieterle F et al. Novel biomarkers of acute kidney toxicity. Clin Pharmacol Ther 2009; 86: 490-496.
4. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2-15. (Pubitemid 27064516)
5. Pinto-Sietsma SJ, Janssen WM, Hillege HL et al. Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. J Am Soc Nephrol 2000; 11: 1882-1888.
6. Tucker BJ, Rasch R, Blantz RC. Glomerular filtration and tubular reabsorption of albumin in preproteinuric and proteinuric diabetic rats. J Clin Invest 1993; 92: 686-694. (Pubitemid 23262386)
7. Birn H, Fyfe JC, Jacobsen C et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000; 105: 1353-1361. (Pubitemid 30322401)
8. Ichimura T, Asseldonk EJ, Humphreys BD et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008; 118: 1657-1668. (Pubitemid 351632370)
9. Ichimura T, Bonventre JV, Bailly V et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273: 4135-4142. (Pubitemid 28103282)
10. Rached E, Hoffmann D, Blumbach K et al. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci 2008; 103: 371-381. (Pubitemid 351659609)
11. Ichimura T, Hung CC, Yang SA et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286: F552-F563. (Pubitemid 38233650)
12. Prozialeck WC, Vaidya VS, Liu J et al. Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int 2007; 72: 985-993. (Pubitemid 47530576)
13. Zhou Y, Vaidya VS, Brown RP et al. Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci 2008; 101: 159-170. (Pubitemid 350239020)
14. Sieber M, Hoffmann D, Adler M et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamicin nephrotoxicity. Toxicol Sci 2009; 109: 336-349.
15. Zhang J, Goering PL, Espandiari P et al. Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine. Toxicol Pathol 2009; 37: 629-643.
16. Lebkowska U, Malyszko J, Lebkowska A et al. Neutrophil gelatinaseassociated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant Proc 2009; 41: 154-157.
17. Makris K, Markou N, Evodia E et al. Urinary neutrophil gelatinaseassociated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009; 47: 79-82.
18. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H et al. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 2009; 41: 158-161.
19. Kuwabara T, Mori K, Mukoyama M et al. Urinary neutrophil gelatinaseassociated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285-294.
20. Hanai J, Mammoto T, Seth P et al. Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem 2005; 280: 13641-13647. (Pubitemid 40517258)
21. Bu DX, Hemdahl AL, Gabrielsen A et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 2006; 169: 2245-2253. (Pubitemid 351181982)
22. Wang Y, Lam KS, Kraegen EW et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007; 53: 34-41. (Pubitemid 46047761)
23. Aigner F, Maier HT, Schwelberger HG et al. Lipocalin-2 regulates the inflammatory response during ischemia and reperfusion of the transplanted heart. Am J Transplant 2007; 7: 779-788. (Pubitemid 46481201)
24. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-1482. (Pubitemid 24003267)
25. Xie Y, Nishi S, Iguchi S et al. Expression of osteopontin in gentamicininduced acute tubular necrosis and its recovery process. Kidney Int 2001; 59: 959-974. (Pubitemid 32206859)
26. Wang EJ, Snyder RD, Fielden MR et al. Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology 2008; 246: 91-100.
27. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008; 48: 463-493. (Pubitemid 351738161)
28. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-1735. (Pubitemid 33104847)
29. Persy VP, Verstrepen WA, Ysebaert DK et al. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/ reperfusion. Kidney Int 1999; 56: 601-611. (Pubitemid 29353158)
30. Dvergsten J, Manivel JC, Correa-Rotter R et al. Expression of clusterin in human renal diseases. Kidney Int 1994; 45: 828-835. (Pubitemid 24094496)
31. Rosenberg ME, Girton R, Finkel D et al. Apolipoprotein J/clusterin prevents a progressive glomerulopathy of aging. Mol Cell Biol 2002; 22: 1893-1902. (Pubitemid 34175004)
32. Xie MJ, Motoo Y, Su SB et al. Expression of clusterin in pancreatic acinar cell injuries in vivo and in vitro XIE2001. Pancreas 2001; 22: 126-134. (Pubitemid 32179166)
33. Han BH, DeMattos RB, Dugan LL et al. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nat Med 2001; 7: 338-343. (Pubitemid 32224350)
34. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci 2000; 25: 95-98. (Pubitemid 30122416)
35. Zhang J, Brown RP, Shaw M et al. Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol 2008; 36: 397-409.